MECHANISM Jun 3, 2026 The Pentadecapeptide Family: BPC-157, TB-500, and Their Relatives A comparison of the most-researched short-chain regeneration peptides
Recent studies have indicated that novel therapeutics can be created using tumor-suppressive peptides in place of existing chemotherapeutics that are ineffective at targeting metastases
doi: 10.3389/fphar.2015.00001 Received 08 October 2014 Accepted 05 January 2015 Published 10 March 2015 Volume 6 - 2015 Edited by Alfonso Pompella, University of Pisa, Italy Reviewed by Peter James King, Queen Mary University of London, UK
Results 8 in vitro studies dealing with different short peptides with different biological functions against oral cavity cells and tissues were included
The result is a molecule with a plasma half-life of approximately 155 to 183 hours (~7 days) enabling once-weekly dosing in research models and clinical protocols while retaining potent, selective activation of the GLP-1 receptor across multiple tissue types including the pancreas, gastrointestinal tract, brain, kidney, liver, and cardiovascular system
